STOCK TITAN

Celcuity To Participate in Jefferies Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Celcuity (Nasdaq: CELC), a clinical-stage biotechnology firm focused on oncology therapies, announced its participation in the Jefferies Global Healthcare Conference from June 4-6, 2024, in New York.

Brian Sullivan, CEO and Co-founder, will engage in a fireside chat at 10:00 a.m. ET on June 6, 2024.

The event will be webcast live at this link: https://wsw.com/webcast/jeff302/celc/1809904, and accessible via the Investors section on Celcuity's website, with a replay available soon after.

Positive
  • Participation in a high-profile event like the Jefferies Global Healthcare Conference can increase Celcuity's visibility among investors.
  • The CEO's fireside chat could provide valuable insights into the company's strategic direction, potentially attracting new investors.
Negative
  • No new clinical or financial data was released, which may disappoint investors looking for concrete updates.
  • Over-reliance on webcast participation without significant announcements might be seen as insufficient to stimulate stock movement.

MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024.

Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 10:00 a.m. ET on Thursday, June 6, 2024. A live webcast of the event will be available using this weblink https://wsw.com/webcast/jeff302/celc/1809904. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.

About Celcuity 
Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is enrolling patients. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is expected to begin enrolling patients in the second quarter of 2025. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and  Twitter.

View source version of release on GlobeNewswire.com

Contacts: 
Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com 
Vicky Hahne, vhahne@celcuity.com 
(763) 392-0123 

ICR Westwicke 
Maria Yonkoski, maria.yonkoski@westwicke.com   
(203) 682-7167


FAQ

What event will Celcuity (CELC) participate in on June 4-6, 2024?

Celcuity will participate in the Jefferies Global Healthcare Conference in New York.

When is Celcuity's CEO scheduled to give a fireside chat?

Brian Sullivan, CEO of Celcuity, is scheduled for a fireside chat at 10:00 a.m. ET on June 6, 2024.

How can I watch Celcuity's presentation at the Jefferies Global Healthcare Conference?

The live webcast will be available at this link: https://wsw.com/webcast/jeff302/celc/1809904 and on the Investors section of Celcuity's website.

Celcuity Inc.

NASDAQ:CELC

CELC Rankings

CELC Latest News

CELC Stock Data

472.66M
29.92M
13.05%
81.47%
9.42%
Biotechnology
Services-medical Laboratories
Link
United States of America
MINNEAPOLIS